ISPOR EUROPE

Jeffrey Brown, PhD is an internationally recognized expert in the use of real-world data to support the evidentiary needs of regulatory agencies and medical product sponsors and an expert in the assessment of data quality of real-world data resources. Dr. Brown has more than 25 years of experience in research using real-world data, most recently as an Associate Professor in the Department of Population Medicine at Harvard Medical School and as a trusted consultant to numerous research groups and pharma companies. Dr. Brown holds a master’s degree in Economics from Tufts University and a PhD in Social Policy from Brandeis University.

Jeff Graham is a recognized expert in real-world data (RWD) strategy, product development, and healthcare analytics. With over 16 years of experience, he has led the creation of scalable data solutions that support regulatory-grade research and commercial insights across the life sciences industry.

Mr. Graham is currently Vice President of Data Solutions at TriNetX, where he leads the development of linked data products and AI/ML-enabled research tools. Previously, he led the Data Innovation department at a Fortune 15 healthcare company, driving enterprise data strategy and innovation.

K. Arnold Chan, MD, ScD, FISPE, is an internationally recognized epidemiologist with more than 30 years of global research experience in academia and the private sector, primarily in the post-marketing evaluation of pharmaceutical agents and vaccines. He has served on the Harvard School of Public Health and National Taiwan University faculty and was Chief Scientist of the epidemiology unit of a Fortune 10 company. Dr. Chan has authored or co-authored more than 150 peer-reviewed articles on pharmacoepidemiology and clinical epidemiology and co-edited a textbook on pharmacoepidemiology and therapeutic risk management.

A seasoned MD Anderson-trained epidemiologist with over 15 years of observational research experience, Dr. Amirian has previously led teams on sponsored real-world research projects at small startups and a Fortune 10 company, where she drove impactful insights from real-world data. She also led the Public Health Portfolio at the Texas Policy Lab, Rice University, focusing on innovative public health initiatives. Before this, she was an Assistant Professor in the Division of Hematology-Oncology at Baylor College of Medicine and was the Associate Director of Data Quality at the Population Sciences Biorepository. Her expertise spans epidemiology, oncology, and data quality management, contributing significantly to advancing medical research and healthcare practices.

Andreas brings a wealth of experience to the TriNetX team, following a distinguished 30-year career in the life sciences industry. Most recently, he served as the CEO of EvidentIQ, a leading provider of technology and data science solutions for clinical research. His career includes senior management roles at ERT/BioClinica and Oracle Health Sciences, where he built a 17-year sales and business development legacy.

As a senior executive with a proven track record in management and leadership, Andreas is known for his deep understanding of life sciences, spanning the entire industry continuum. His expertise encompasses pharmacovigilance, drug safety, regulatory affairs, and end-to-end eClinical processes, with a strong focus on business process optimization, outsourcing, and information technology.

Andreas’s career reflects a commitment to advancing the life sciences industry through strategic innovation and effective leadership, making him a valuable asset to TriNetX and a respected figure in European oncology research.

Markus is a seasoned biopharmaceutical expert specializing in oncology and rare diseases, boasting over 20 years of extensive experience in leadership positions across renowned organizations such as Ipsen Pharma, CSL Vifor, MorphoSys, among others. Proficient in clinical development and Medical Affairs, experimental and real-world evidence generation, Markus has successfully navigated various stages of drug development—from discovery to market launch—with a keen focus on advancing oncological and rare disease therapies for tangible patient benefits. Having achieved significant milestones in oncology and rare disease therapeutics, Markus now channels his diverse expertise towards broader pursuits in epidemiology, health service research, and the real-world impact of oncological treatments. Holding a PhD in biochemistry and pharmacology, Markus has contributed academically to esteemed institutions such as the University of Würzburg, Germany and the Karolinska Institutet, Stockholm, Sweden.

Zuzana is a Data Scientist at Trinetx Oncology, a wholly owned subsidiary of TriNetX, specializing in real-world data oncology research. She focuses on innovation and data quality to transform raw data into meaningful insights that support cancer research and patient care.

By leveraging data science, Zuzana addresses challenges in oncology, ensuring high standards of data accuracy and reliability. She collaborates closely with researchers, clinicians, and other data analysts to produce scientifically robust and clinically applicable findings.

Passionate about continuous learning and professional growth, Zuzana’s work aims to enhance the understanding of cancer and improve patient outcomes through informed and personalized treatments. Her efforts bridge the gap between data science and clinical practice, driving advancements in cancer research and patient care.

Dr. O’Rourke has completed an NIH post-doctoral fellowship in biomedical informatics at Massachusetts General Hospital. She has served as a faculty member at Harvard Medical School, a principal investigator at the Lurie Center for Autism, and has authored and co-authored over a dozen publications on various topics. During her five-year tenure at TriNetX, Dr. O’Rourke has held roles on the engineering, data science, and research teams, most recently focusing on leading and co-leading client research projects and publishing her research utilizing TriNetX’s real-world data. Her research interests focus on using machine learning with real-world data to address various questions in oncology research.

Zuzanna Drebert is a data specialist with over seven years of experience working with real-world medical data. With a PhD in Experimental Cancer Research from Ghent University in Belgium, she combines her biomedical expertise with technical skills to help solve problems and drive advancements in healthcare and research.

As a Data Scientist at TriNetX, Zuzanna supports both internal and external research projects by leveraging her experience in data analysis, machine learning, data visualization, and domain knowledge. She also contributes to experiments exploring various methods for extracting data from free-text clinical notes.

Zuzanna is passionate about learning, experimenting with new ideas and techniques, and continuously improving her work to achieve meaningful outcomes.

Marley Boyd, Senior Director of Analytics at TriNetX, is a statistician with extensive experience in real-world research and expertise in multiple therapeutic areas, including oncology and chronic kidney disease. After training at Sam Houston State University, Mr. Boyd has spent ten years developing and leading analytic teams working on sponsored real-world research studies at a mid-size contract research organization and a Fortune 10 company. Mr. Boyd has authored or co-authored over 25 scientific publications. A list of his publications can be found here.

His expertise spans biostatistics, oncology, and automation of analytics, contributing extensively to advancing medical research and healthcare practices.

Kai Strobel is Senior Data Analyst and Lead Epidemiologist at TriNetX Oncology GmbH in Freiburg, Germany. Kai has years of experience in collection of regulatory-grade RWD in Germany and other European countries (UK, France, and Spain), and the generation of RWE for research and successful HTA applications within the field of oncology. His experience broadly covers Health Economics and Outcomes Research (HEOR) topics with a focus on haematology-oncology, having published on multiple myeloma epidemiological trends in Germany and chronic lymphocytic leukemia treatment in the clinical reality in Germany and Spain.

Kai aims to contribute to a future where data-driven decisions significantly enhance the efficacy and efficiency of oncological treatments for meeting unmet needs and improving patient outcomes.

Lisa Merker is a data scientist with a biomedical background. She holds an M.Sc. in Neuroscience from the University of Freiburg and has been working at TriNetX Oncology GmbH for four years, contributing to real-world evidence research and innovation.

Her work focuses on data quality, harmonization, reproducibility, and transforming complex clinical datasets into scientifically grounded results. Lisa supports internal and external research projects through data analysis, visualization, and collaborative problem-solving, and regularly presents her work in scientific poster sessions.

With a passion for continuous learning and interdisciplinary collaboration, Lisa applies data science to improve healthcare outcomes and support patient-centered research.